Find a Clinical Trial

Find a clinical trial underway at the OSUCCC – James.

Search by Keyword

(i.e. John Smith, 197102, Phase 3)

Showing 1-10 of 289

Open To Accrual

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

Protocol NumberOSU-19176

Open To Accrual

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

Protocol NumberOSU-23427

Open To Accrual

A Study of V940 Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)

Protocol NumberOSU-23367

Open To Accrual

REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1

Protocol NumberOSU-23243

Open To Accrual

Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)

Protocol NumberOSU-23428

Open To Accrual

Safety, PK, PD, Dosing, and Efficacy of RLS-0071for the Treatment of Hospitalized Patients With Steroid-Refractory Acute Graft-versus-Host Disease

Protocol NumberOSU-24157

Open To Accrual

A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas

Protocol NumberOSU-22311

Open To Accrual

OSU-24210: SAR443579 Comb Aza + Venet Adlt CD123 ND-AML Ineligible Intensive Chemo - Substudy 01

Protocol NumberOSU-24210

Open To Accrual

Phase 1a/1b Study of STK-012 Monotherapy and in Combination With Pembrolizumab in Patients With Solid Tumors

Protocol NumberOSU-23369

Open To Accrual

OSU-24220: ZE46-0134 Adlts FLT3 mutated Relapsed or Refractory Acute Myeloid Leukemia (AML)

Protocol NumberOSU-24220